| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H27N3O4S |
| Molecular Weight | 441.543 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C1=CC=CC2=C(C=CC=C12)S(=O)(=O)NC3=CC=C(NC(=O)C(C)(C)CO)C=C3
InChI
InChIKey=OSQAKHSYTKBSPB-UHFFFAOYSA-N
InChI=1S/C23H27N3O4S/c1-23(2,15-27)22(28)24-16-11-13-17(14-12-16)25-31(29,30)21-10-6-7-18-19(21)8-5-9-20(18)26(3)4/h5-14,25,27H,15H2,1-4H3,(H,24,28)
| Molecular Formula | C23H27N3O4S |
| Molecular Weight | 441.543 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tomeglovir (BAY 38-4766) is a human cytomegalovirus (CMV) terminase complex inhibitor. Treatment with BAY 38-4766 reduced both viremia and DNAemia, as determined by a real-time PCR assay, following guinea pig cytomegalovirus (GPCMV) infection of cyclophosphamide-immunosuppressed strain 2 guinea pigs. BAY 38-4766 also reduced mortality following lethal GPCMV challenge in immunosuppressed Hartley guinea pigs. a combination of BAY 38-4766 with anti-cytomegalovirus drug ganciclovir showed antagonism. Interaction of viral DNA processing inhibitor 2-bromo-5,6-dichloro-1beta-D-ribofuranosyl benzimidazole (BDCRB) with BAY 38-4766 showed a mixed pattern of synergy and antagonism. Tomeglovir had been in phase II clinical trials by Bayer for the treatment of CMV infection. However, this development was discontinued.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 0.34 µM [IC50] |
